FDA Indications part 1

Benazepril

Hypertension

Lisinopril

Hypertension

Enalapril

1) Hypertension

2) Symptomatic congestive heart failure;

3) Asymptomatic left ventricular dysfunction (where indicated on label formulations).

Ramipril

1) Hypertension

2) (Some ramipril labels also include post-MI/heart-failure secondary indications — check specific brand label.)

Losartan

1) Hypertension

2) (Certain losartan brands: left ventricular hypertrophy indication / additional labeling — check specific label.)

Olmesartan

Hypertension

Irbesartan

1) Hypertension

2) Diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine and proteinuria.

Valsartan

1) Hypertension

2) Heart failure (reduce hospitalization in adults, specific product labels).

3) Left ventricular dysfunction post-MI (product dependent).

Hydrochlorothiazide (HCTZ)

1) Hypertension — management either as sole agent or in combination.

2) Adjunctive therapy for edema associated with congestive heart failure, hepatic cirrhosis, corticosteroid/estrogen therapy, and some renal dysfunction (label-dependent).

Chlorthalidone

1) Hypertension

2) Adjunctive therapy for edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid/estrogen therapy (product labels vary).

Furosemide (Lasix)

1) Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease (including nephrotic syndrome).

2) Hypertension (in some product labeling).

Triamterene/HCTZ (combination)

1) Hypertension and edema — indicated for patients in whom hypokalemia is a concern or for whom a potassium-sparing effect is desired; not for initial therapy except in selected patients (see label).

Spironolactone

1) NYHA Class III-IV heart failure with reduced ejection fraction — to increase survival/manage edema and reduce hospitalization.

2) Primary hyperaldosteronism — diagnostic and therapeutic uses (label specifics).

Amlodipine

1) Hypertension

2) Chronic stable angina and vasospastic (Prinzmetal) angina (per product labeling/clinical use).

Nifedipine (ER formulations)

1) Hypertension (ER products)

2) Management of vasospastic (Prinzmetal) angina (certain ER product labels).

Verapamil

1) Hypertension — (sustained/ER formulations).

2) Angina (including vasospastic and chronic stable angina). 3) (IV/product labels include supraventricular tachycardia indications — see specific label for IV use).

Diltiazem

1) Hypertension (ER formulations)

2) Chronic stable angina and vasospastic angina

3) (IV formulations indicated for rate control in atrial fibrillation/flutter and certain supraventricular tachycardias — see IV label).

Atenolol

1) Hypertension

2) Angina pectoris (long-term management).

3. AMI

Metoprolol Tartrate

1) Hypertension

2) Angina pectoris (long-term treatment).

3) Acute myocardial infarction — reduce cardiovascular mortality in certain stable patients.

Metoprolol Succinate

1) Hypertension

2) Angina pectoris (long-term).

3) Heart failure (stable, to reduce cardiovascular mortality and hospitalizations) — extended-release product labeling.

Nebivolol

1) Hypertension

Bisoprolol

1) Hypertension

Propranolol

1) Hypertension

2) Angina pectoris.

3) Myocardial infarction (secondary prevention in specified settings).

4) Certain arrhythmias and other product-specific indications (see label for IV and ER formulations).

Carvedilol

1) Mild to severe chronic heart failure (to increase survival and reduce hospitalization).

2) Left ventricular dysfunction following myocardial infarction in clinically stable patients (to reduce mortality). 3) Hypertension.

Doxazosin

1) Hypertension — treatment to lower blood pressure.

2) Benign prostatic hyperplasia (BPH) — treatment of urinary outflow obstruction and irritative symptoms (label includes BPH indication).

Terazosin

1) Benign prostatic hyperplasia (BPH) — symptomatic treatment.

2) Hypertension (some labels include use for hypertension).

Clonidine

1) Hypertension — treatment to lower blood pressure (oral formulations).

2) Certain ER clonidine products are FDA-approved for Attention Deficit Hyperactivity Disorder (ADHD) (brand-specific labeling).

3) IV/epidural clonidine has niche indications (see specific product label).

Hydralazine

1) Severe essential hypertension when oral route is not possible or urgent lowering required (IV label).

2) Oral hydralazine: treatment of hypertension (label specifics) and adjunct treatment in pregnancy-related hypertension in some contexts (see label).

Guanfacine

1) (Oral immediate-release guanfacine) — antihypertensive (older labeling).

2) Guanfacine ER (brand) — Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy or adjunctive therapy (brand label).

Amiodarone

1) Life-threatening recurrent ventricular fibrillation and hemodynamically unstable sustained ventricular tachycardia (primary severe arrhythmia indications).

2) (Oral product labels: reserved for life-threatening arrhythmias because of toxicity; IV labels contain acute arrhythmia uses).

Digoxin

1) Heart failure (to increase contractile force in certain patients; product labeling describes specific use).

2) Control of ventricular response in chronic atrial fibrillation (rate control) — see label for specifics.

Isosorbide mononitrate (Imdur)

1) Prevention of angina pectoris due to coronary artery disease (prophylactic treatment; Imdur sustained-release formulations).

Nitroglycerin

1) Acute angina pectoris — sublingual tablets and spray for acute relief.

2) Prophylaxis of angina — transdermal patches/ointment for prevention (product-dependent).

3) IV infusion for acute perioperative or ischemic situations (hospital settings) — see specific label.